{"id":"NCT03051217","sponsor":"UCB Biopharma S.P.R.L.","briefTitle":"A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis","officialTitle":"Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-02-21","primaryCompletion":"2018-11-19","completion":"2019-01-16","firstPosted":"2017-02-13","resultsPosted":"2019-12-11","lastUpdate":"2022-01-04"},"enrollment":127,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Psoriasis","Generalized Pustular Psoriasis and Erythrodermic Psoriasis"],"interventions":[{"type":"OTHER","name":"Placebo","otherNames":["PBO"]},{"type":"DRUG","name":"Certolizumab Pegol","otherNames":["Cimzia","CDP870","CZP"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"CZP 200 mg","type":"EXPERIMENTAL"},{"label":"CZP 400 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to demonstrate the efficacy and safety of Certolizumab Pegol (CZP) in the treatment of moderate to severe chronic plaque Psoriasis (PSO) in Japanese subjects.","primaryOutcome":{"measure":"Percentage of Subjects Achieving a 75 % or Higher Improvement in Psoriasis Area and Severity Index (PASI) Score at Week 16","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo (FAS)","deltaMin":7.9,"sd":null},{"arm":"CZP 200 mg Q2W (FAS)","deltaMin":73,"sd":null},{"arm":"CZP 400 mg Q2W (FAS)","deltaMin":87.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":33,"countries":["Japan"]},"refs":{"pmids":["34826124","35622315","33886085","33606269"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":26},"commonTop":["Nasopharyngitis","Psoriasis","Eczema","Cough","Headache"]}}